Sensing the Tiniest Change
A new biomarker sensing technology provides sensitive, specific monitoring for a wide range of patients
Menno Prins | | Quick Read
Molecules that are essential for the body, such as proteins and hormones, can often yield significant insight into a patient’s health status. But most of these molecules are present in the blood in pico- or nanomolar concentrations – comparable to one grain of sugar dissolved in an Olympic swimming pool. The best-known assay to measure such low concentrations outside the body is ELISA, a test in which the sample passes through an elaborate process with multiple steps and biochemical reagents to yield a single concentration value. In contrast, continuous monitoring dynamically follows biomarker concentration in solution, leading to a stream of data rather than an isolated result. For continuous monitoring, molecular binding must be reversible and lead directly to a measurable signal without consumption or production of chemical reactants. The sensing principle should be self-contained, reversible, and stable over a long period of time. Still, the assay should be as sensitive and as specific as ELISA. That’s the challenge we are addressing (1).
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine